BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 24405493)

  • 21. Cardiovascular variability during treatment with haloperidol, olanzapine or risperidone in recent-onset schizophrenia.
    Hempel RJ; Tulen JH; van Beveren NJ; Röder CH; Hengeveld MW
    J Psychopharmacol; 2009 Aug; 23(6):697-707. PubMed ID: 18562420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder.
    Bobo WV; Bonaccorso S; Jayathilake K; Meltzer HY
    Psychiatry Res; 2011 Sep; 189(2):200-7. PubMed ID: 21802150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
    Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
    Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of adjunctive aripiprazole on QT interval: A 12-week open label study in patients on olanzapine, clozapine or risperidone.
    Pilunthanakul T; Ting MQJ; Lee J; Gupta B
    Hum Psychopharmacol; 2023 May; 38(3):e2863. PubMed ID: 36810742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
    J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of olanzapine and risperidone in 367 first-episode patients with non-affective or affective psychosis: results of an open retrospective medical record study.
    Lambert M; Conus P; Schimmelmann BG; Eide P; Ward J; Yuen H; Schacht M; Edwards J; Naber D; McGorry PD
    Pharmacopsychiatry; 2005 Sep; 38(5):206-13. PubMed ID: 16189747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
    Alptekin K; Hafez J; Brook S; Akkaya C; Tzebelikos E; Ucok A; El Tallawy H; Danaci AE; Lowe W; Karayal ON
    Int Clin Psychopharmacol; 2009 Sep; 24(5):229-38. PubMed ID: 19531959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration.
    Ritchie CW; Chiu E; Harrigan S; MacFarlane S; Mastwyk M; Halliday G; Hustig H; Hall K; Hassett A; O'Connor DW; Opie J; Nagalingam V; Snowdon J; Ames D
    Int J Geriatr Psychiatry; 2006 Feb; 21(2):171-9. PubMed ID: 16416458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition.
    Harrigan EP; Miceli JJ; Anziano R; Watsky E; Reeves KR; Cutler NR; Sramek J; Shiovitz T; Middle M
    J Clin Psychopharmacol; 2004 Feb; 24(1):62-9. PubMed ID: 14709949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model.
    Vera-Llonch M; Delea TE; Richardson E; Rupnow M; Grogg A; Oster G
    Value Health; 2004; 7(5):569-84. PubMed ID: 15367252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
    Saddichha S; Ameen S; Akhtar S
    J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients.
    Scheltema Beduin AA; Swets M; Machielsen M; Korver N;
    J Clin Psychiatry; 2012 Nov; 73(11):1395-402. PubMed ID: 23218156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risperidone and olanzapine versus another first generation antipsychotic in patients with schizophrenia inadequately responsive to first generation antipsychotics.
    Chen JJ; Chan HY; Chen CH; Gau SS; Hwu HG
    Pharmacopsychiatry; 2012 Mar; 45(2):64-71. PubMed ID: 22086749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.
    Garman PM; Ried LD; Bengtson MA; Hsu C; McConkey JR
    J Am Pharm Assoc (2003); 2007; 47(3):373-8. PubMed ID: 17510032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment persistence: a comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents.
    Ren XS; Qian S; Lee AF; Herz L; Miller DR; Kazis LE
    J Clin Pharm Ther; 2006 Feb; 31(1):57-65. PubMed ID: 16476121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Switching to risperidone after unsuccessful treatment of olanzapine in the first-episode schizophrenia: an open trial.
    Takahashi H; Yoshida K; Ishigooka J; Higuchi H
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1067-72. PubMed ID: 16759777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, 4-month study.
    Kinon BJ; Liu-Seifert H; Ahl J; Ahmed S; Baker RW
    Ann N Y Acad Sci; 2004 Dec; 1032():295-6. PubMed ID: 15677433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine.
    Wilton LV; Heeley EL; Pickering RM; Shakir SA
    J Psychopharmacol; 2001 Jun; 15(2):120-6. PubMed ID: 11448085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study.
    Meyer JM; Pandina G; Bossie CA; Turkoz I; Greenspan A
    Clin Ther; 2005 Dec; 27(12):1930-41. PubMed ID: 16507379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A pilot observational crossover study of QTc interval changes associated with switching between olanzapine and risperidone.
    Huang CL; Su KP; Hsu HB; Pariante CM
    J Clin Psychiatry; 2007 May; 68(5):803-5. PubMed ID: 17503999
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.